论文部分内容阅读
目的:研究观察纤溶酶治疗突发性聋的临床疗效及安全性。方法:71例(77耳)突聋患者随机分成纤溶酶治疗组36例(38耳)和巴曲酶对照组35例(39耳),在2组的一般治疗完全相同的基础上,治疗组接受以纤溶酶为主的综合治疗,而对照组则接受以巴曲酶为主的综合治疗。结果:治疗组有效率78.8%,对照组有效率81.5%,2组比较差异无统计学意义(P>0.05);2组均未出现明显不良反应。结论:纤溶酶治疗突发性聋与巴曲酶的疗效相同,无明显不良反应,但较巴曲酶相对价廉,值得进一步推广应用。
Objective: To study the clinical efficacy and safety of plasmin in the treatment of sudden deafness. Methods: A total of 71 patients (77 ears) with sudden deafness were randomly divided into 36 cases (38 ears) treated with fibrinolytic enzyme and 35 cases (39 ears) treated with batroxobin in the control group. On the basis of the same general treatment, Group received plasmin-based comprehensive treatment, while the control group received batroxobin-based comprehensive treatment. Results: The effective rate was 78.8% in the treatment group and 81.5% in the control group. There was no significant difference between the two groups (P> 0.05). No obvious adverse reactions were found in the two groups. CONCLUSION: Plasmin is effective in treating sudden deafness and batroxobin with no obvious side effects, but it is cheaper than batroxobin and should be further popularized and applied.